Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease

Cytotherapy

Volumn 16, Issue 11, 2014, Pages 1453-1466

  Davies, James O J ^a   Stringaris, Kate ^a   Barrett, A John ^b   Rezvani, Katayoun ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

C type lectin; Graft versus leukemia; Immunotherapy; Killer immunoglobulin like receptors; Natural cytotoxicity receptors; Natural killer

Indexed keywords

CD16 ANTIGEN; CD34 ANTIGEN; CD94 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; LENALIDOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; RITUXIMAB; T LYMPHOCYTE RECEPTOR; THALIDOMIDE; LECTIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL KILLING; CELL SELECTION; CELL THERAPY; CELL TRANSFER; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; GENOTYPE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; KIR GENE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; NATURAL KILLER CELL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; ADOPTIVE TRANSFER; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; LEUKEMIA; PROCEDURES; TRANSPLANTATION;

ADOPTIVE TRANSFER; GRAFT VS LEUKEMIA EFFECT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LEUKEMIA; RECEPTORS, KIR;

EID: 84912529475     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.03.009     Document Type: Review

References (136)

1. Lanier L.L., Le A.M., Civin C.I., Loken M.R., Phillips J.H. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. JImmunol 1986, 136:4480-4486.
2. Nagler A., Lanier L.L., Cwirla S., Phillips J.H. Comparative studies of human FcRIII-positive and negative natural killer cells. JImmunol 1989, 143:3183-3191.
3. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood 2001, 97:3146-3151.
4. Campbell J.J., Qin S., Unutmaz D., Soler D., Murphy K.E., Hodge M.R., et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. JImmunol 2001, 166:6477-6482.
5. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
6. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
7. Fischer U., Utke K., Somamoto T., Kollner B., Ototake M., Nakanishi T. Cytotoxic activities of fish leucocytes. Fish Shellfish Immunol 2006, 20:209-226.
8. Single R.M., Martin M.P., Gao X., Meyer D., Yeager M., Kidd J.R., et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 2007, 39:1114-1119.
9. Lowin B., Peitsch M.C., Tschopp J. Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Curr Top Microbiol Immunol 1995, 198:1-24.
10. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9:503-510.
11. Bezman N.A., Cedars E., Steiner D.F., Blelloch R., Hesslein D.G., Lanier L.L. Distinct requirements of microRNAs in NK cell activation, survival, and function. JImmunol 2010, 185:3835-3846.
12. Ma F., Xu S., Liu X., Zhang Q., Xu X., Liu M., et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 2011, 12:861-869.
13. Sullivan R.P., Leong J.W., Schneider S.E., Keppel C.R., Germino E., French A.R., et al. MicroRNA-deficient NK cells exhibit decreased survival but enhanced function. JImmunol 2012, 188:3019-3030.
14. Long E.O. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999, 17:875-904.
15. Ljunggren H.G., Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
16. Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol Rev 2006, 214:155-160.
17. Davis D.M., Chiu I., Fassett M., Cohen G.B., Mandelboim O., Strominger J.L. The human natural killer cell immune synapse. Proc Natl Acad Sci U S A 1999, 96:15062-15067.
18. van der Merwe P.A., Dushek O. Mechanisms for T cell receptor triggering. Nat Rev Immunol 2010, 11:47-55.
19. Kohler K., Xiong S., Brzostek J., Mehrabi M., Eissmann P., Harrison A., et al. Matched sizes of activating and inhibitory receptor/ligand pairs are required for optimal signal integration by human natural killer cells. PLoS One 2010, 5:e15374.
20. Khakoo S.I., Rajalingam R., Shum B.P., Weidenbach K., Flodin L., Muir D.G., et al. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. Immunity 2000, 12:687-698.
21. Parham P. Immunogenetics of killer-cell immunoglobulin-like receptors. Tissue Antigens 2003, 62:194-200.
22. Naumova E., Mihaylova A., Stoitchkov K., Ivanova M., Quin L., Toneva M. Prevalence of inhibitory over activating KIR signals in melanoma patients could contribute to the tumor escape of the immunosurveillance. Genes Immun 2004, 5. S2-S.
23. Weiner G.J. Rituximab: mechanism of action. Semin Hematol 2010, 47:115-123.
24. Carrington M., Wang S., Martin M.P., Gao X.J., Schiffman M., Cheng J., et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. JExp Med 2005, 201:1069-1075.
25. Kovacic M.B., Martin M., Gao X.J., Fuksenko T., Chen C.J., Cheng Y.J., et al. Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma. Cancer Epidem Biomar 2005, 14:2673-2677.
26. Scquizzato E., Teramo A., Miorin M., Facco M., Piazza F., Noventa F., et al. Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia 2007, 21:1060-1069.
27. Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R., Caligiuri M.A. The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. Blood 2009, 113:2470-2477.
28. Gabriel I.H., Sergeant R., Szydlo R., Apperley J.F., DeLavallade H., Alsuliman A., et al. Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood 2010, 116:2033-2039.
29. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
30. Lamy T., Loughran T.P. How I treat LGL leukemia. Blood 2011, 117:2764-2774.
31. Verheyden S., Demanet C. Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions. Leukemia 2006, 20:1437-1438.
32. Venstrom J.M., Pittari G., Gooley T.A., Chewning J.H., Spellman S., Haagenson M., et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. NEngl J Med 2012, 367:805-816.
33. Stringaris K., Adams S., Uribe M., Eniafe R., Wu C.O., Savani B.N., et al. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:1257-1264.
34. Marin D., Gabriel I.H., Ahmad S., Foroni L., de Lavallade H., Clark R., et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 2012, 26:296-302.
35. Ali S., Sergeant R., O'Brien S.G., Foroni L., Hedgley C., Gerrard G., et al. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood 2012, 120:697-698.
36. Dorfman J.R., Raulet D.H. Major histocompatibility complex genes determine natural killer cell tolerance. Eur J Immunol 1996, 26:151-155.
37. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.J., Yang L., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
38. Anfossi N., Andre P., Guia S., Falk C.S., Roetynck S., Stewart C.A., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342.
39. Parham P., Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013, 13:133-144.
40. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
41. Giebel S., Locatelli F., Lamparelli T., Velardi A., Davies S., Frumento G., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-819.
42. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
43. North J., Bakhsh I., Marden C., Pittman H., Addison E., Navarrete C., et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. JImmunol 2007, 178:85-94.
44. Sabry M., Tsirogianni M., Bakhsh I.A., North J., Sivakumaran J., Giannopoulos K., et al. Leukemic priming of resting NK cells is killer Ig-like receptor independent but requires CD15-mediated CD2 ligation and natural cytotoxicity receptors. JImmunol 2011, 187:6227-6234.
45. Carbone E., Neri P., Mesuraca M., Fulciniti M.T., Otsuki T., Pende D., et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005, 105:251-258.
46. Salih H.R., Rammensee H.G., Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. JImmunol 2002, 169:4098-4102.
47. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
48. Waldhauer I., Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006, 66:2520-2526.
49. Salih H.R., Antropius H., Gieseke F., Lutz S.Z., Kanz L., Rammensee H.G., et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003, 102:1389-1396.
50. Doubrovina E.S., Doubrovin M.M., Vider E., Sisson R.B., O'Reilly R.J., Dupont B., et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. JImmunol 2003, 171:6891-6899.
51. Wu J.D., Higgins L.M., Steinle A., Cosman D., Haugk K., Plymate S.R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. JClin Invest 2004, 114:560-568.
52. Jinushi M., Takehara T., Tatsumi T., Kanto T., Groh V., Spies T., et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003, 104:354-361.
53. Raffaghello L., Prigione I., Airoldi I., Camoriano M., Levreri I., Gambini C., et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004, 6:558-568.
54. Brenner C.D., King S., Przewoznik M., Wolters I., Adam C., Bornkamm G.W., et al. Requirements for control of B-cell lymphoma by NK cells. Eur J Immunol 2010, 40:494-504.
55. Sconocchia G., Lau M., Provenzano M., Rezvani K., Wongsena W., Fujiwara H., et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 2005, 106:3666-3672.
56. Yong A.S., Keyvanfar K., Hensel N., Eniafe R., Savani B.N., Berg M., et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009, 113:875-882.
57. Jedema I., van der Werff N.M., Barge R.M., Willemze R., Falkenburg J.H. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004, 103:2677-2682.
58. Pietra G., Manzini C., Rivara S., Vitale M., Cantoni C., Petretto A., et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012, 72:1407-1415.
59. Curti A., Pandolfi S., Valzasina B., Aluigi M., Isidori A., Ferri E., et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007, 109:2871-2877.
60. Stringaris K., Sekine T., Khoder A., Alsuliman A., Razzaghi B., Sargeant R., et al. Leukemia-induced phenotypic and functional defects in natural killercells predict failure to achieve remission in acute myeloid leukemia. Haematologica 2014.
61. Lamb L.S., Gee A.P., Henslee-Downey P.J., Geier S.S., Hazlett L., Pati A.R., et al. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors. Bone Marrow Transplant 1998, 21:461-471.
62. Cooley S., McCullar V., Wangen R., Bergemann T.L., Spellman S., Weisdorf D.J., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005, 106:4370-4376.
63. Morishima Y., Yabe T., Matsuo K., Kashiwase K., Inoko H., Saji H., et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007, 13:315-328.
64. Davies S.M., Ruggieri L., DeFor T., Wagner J.E., Weisdorf D.J., Miller J.S., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants: killer immunoglobulin-like receptor. Blood 2002, 100:3825-3827.
65. Farag S.S., Bacigalupo A., Eapen M., Hurley C., Dupont B., Caligiuri M.A., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006, 12:876-884.
66. Ruggeri L., Mancusi A., Capanni M., Urbani E., Carotti A., Aloisi T., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
67. Kroger N., Shaw B., Iacobelli S., Zabelina T., Peggs K., Shimoni A., et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005, 129:631-643.
68. Clausen J., Wolf D., Petzer A.L., Gunsilius E., Schumacher P., Kircher B., et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007, 148:520-528.
69. Penack O., Fischer L., Gentilini C., Nogai A., Muessig A., Rieger K., et al. The type of ATG matters: natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol 2007, 18:85-87.
70. Leung W., Iyengar R., Turner V., Lang P., Bader P., Conn P., et al. Determinants of antileukemia effects of allogeneic NK cells. JImmunol 2004, 172:644-650.
71. Grzywacz B., Miller J.S., Verneris M.R. Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol 2008, 21:467-483.
72. Miller J.S., Blazar B.R. Control of acute myeloid leukemia relapse: dance between KIRs and HLA. NEngl J Med 2012, 367:866-868.
73. Joncker N.T., Shifrin N., Delebecque F., Raulet D.H. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. JExp Med 2010, 207:2065-2072.
74. Cook M., Briggs D., Craddock C., Mahendra P., Milligan D., Fegan C., et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 2006, 107:1230-1232.
75. Chen C., Busson M., Rocha V., Appert M.L., Lepage V., Dulphy N., et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006, 38:437-444.
76. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. NEngl J Med 1985, 313:1485-1492.
77. Law T.M., Motzer R.J., Mazumdar M., Sell K.W., Walther P.J., O'Connell M., et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995, 76:824-832.
78. Denman C.J., Senyukov V.V., Somanchi S.S., Phatarpekar P.V., Kopp L.M., Johnson J.L., et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 2012, 7:e30264.
79. Shah N., Martin-Antonio B., Yang H., Ku S., Lee D.A., Cooper L.J.N., et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013, 8:e76781.
80. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. JClin Oncol 2010, 28:955-959.
81. Shi J., Tricot G., Szmania S., Rosen N., Garg T.K., Malaviarachchi P.A., et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008, 143:641-653.
82. Klingemann H., Grodman C., Cutler E., Duque M., Kadidlo D., Klein A.K., et al. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. Transfusion 2013, 53:412-418.
83. Bachanova V., Burns L.J., McKenna D.H., Curtsinger J., Panoskaltsis-Mortari A., Lindgren B.R., et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 2010, 59:1739-1744.
84. Brehm C., Huenecke S., Quaiser A., Esser R., Bremm M., Kloess S., et al. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS One 2011, 6:e27351.
85. Lundqvist A., Berg M., Smith A., Childs R.W. Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells. JCancer 2011, 2:383-385.
86. Arai S., Meagher R., Swearingen M., Myint H., Rich E., Martinson J., et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008, 10:625-632.
87. Soriani A., Zingoni A., Cerboni C., Iannitto M.L., Ricciardi M.R., Di Gialleonardo V., et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009, 113:3503-3511.
88. Fionda C., Soriani A., Malgarini G., Iannitto M.L., Santoni A., Cippitelli M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. JImmunol 2009, 183:4385-4394.
89. Diermayr S., Himmelreich H., Durovic B., Mathys-Schneeberger A., Siegler U., Langenkamp U., et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008, 111:1428-1436.
90. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
91. Tai Y.T., Li X.F., Catley L., Coffey R., Breitkreutz I., Bae J., et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005, 65:11712-11720.
92. Hsu A.K., Quach H., Tai T., Prince H.M., Harrison S.J., Trapani J.A., et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011, 117:1605-1613.
93. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005, 128:192-203.
94. Benson D.M., Bakan C.E., Mishra A., Hofmeister C.C., Efebera Y., Becknell B., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: atherapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010, 116:2286-2294.
95. Shi J., Tricot G.J., Garg T.K., Malaviarachchi P.A., Szmania S.M., Kellum R.E., et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 2008, 111:1309-1317.
96. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004, 64:4664-4669.
97. Levy R., Weng W.K. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. JClin Oncol 2003, 21:3940-3947.
98. Vance B.A., Huizinga T.W., Wardwell K., Guyre P.M. Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. JImmunol 1993, 151:6429-6439.
99. Wu J., Edberg J.C., Redecha P.B., Bansal V., Guyre P.M., Coleman K., et al. Anovel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. JClin Invest 1997, 100:1059-1070.
100. Paolino M., Choidas A., Wallner S., Pranjic B., Uribesalgo I., Loeser S., et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 2014.
101. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365:725-733.
102. Billadeau D.D., Upshaw J.L., Schoon R.A., Dick C.J., Leibson P.J. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003, 4:557-564.
103. Colonna M., Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995, 268:405-408.
104. Wagtmann N., Biassoni R., Cantoni C., Verdiani S., Malnati M.S., Vitale M., et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 1995, 2:439-449.
105. D'Andrea A., Chang C., Franz-Bacon K., McClanahan T., Phillips J.H., Lanier L.L. Molecular cloning of NKB1: a natural killer cell receptor for HLA-B allotypes. JImmunol 1995, 155:2306-2310.
106. Vivian J.P., Duncan R.C., Berry R., O'Connor G.M., Reid H.H., Beddoe T., et al. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 2011, 479:401-405.
107. Houchins J.P., Lanier L.L., Niemi E.C., Phillips J.H., Ryan J.C. Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C. JImmunol 1997, 158:3603-3609.
108. Mingari M.C., Ponte M., Bertone S., Schiavetti F., Vitale C., Bellomo R., et al. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci U S A 1998, 95:1172-1177.
109. Derre L., Corvaisier M., Pandolfino M.C., Diez E., Jotereau F., Gervois N. Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. JImmunol 2002, 168:4864-4870.
110. Michaelsson J., Teixeira de Matos C., Achour A., Lanier L.L., Karre K., Soderstrom K. Asignal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. JExp Med 2002, 196:1403-1414.
111. Houchins J.P., Yabe T., McSherry C., Bach F.H. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. JExp Med 1991, 173:1017-1020.
112. Shum B.P., Flodin L.R., Muir D.G., Rajalingam R., Khakoo S.I., Cleland S., et al. Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. JImmunol 2002, 168:240-252.
113. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
114. Eagle R.A., Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007, 7:737-744.
115. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
116. Viny A.D., Clemente M.J., Jasek M., Askar M., Ishwaran H., Nowacki A., et al. MICA polymorphism identified by whole genome array associated with NKG2D-mediated cytotoxicity in T-cell large granular lymphocyte leukemia. Haematologica 2010, 95:1713-1721.
117. Vitale M., Bottino C., Sivori S., Sanseverino L., Castriconi R., Marcenaro E., et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. JExp Med 1998, 187:2065-2072.
118. Pessino A., Sivori S., Bottino C., Malaspina A., Morelli L., Moretta L., et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. JExp Med 1998, 188:953-960.
119. Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T.I., Bushkin Y., et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055-1060.
120. El-Sherbiny Y.M., Meade J.L., Holmes T.D., McGonagle D., Mackie S.L., Morgan A.W., et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007, 67:8444-8449.
121. Delahaye N.F., Rusakiewicz S., Martins I., Menard C., Roux S., Lyonnet L., et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011, 17:700-707.
122. Meyaard L., Adema G.J., Chang C., Woollatt E., Sutherland G.R., Lanier L.L., et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997, 7:283-290.
123. Tangye S.G., Cherwinski H., Lanier L.L., Phillips J.H. 2B4-mediated activation of human natural killer cells. Mol Immunol 2000, 37:493-501.
124. Vaidya S.V., Stepp S.E., McNerney M.E., Lee J.K., Bennett M., Lee K.M., et al. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. JImmunol 2005, 174:800-807.
125. Howe E.C., Wlodarski M., Ball E.J., Rybicki L., Maciejewski J.P. Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes. Exp Hematol 2005, 33:1357-1362.
126. Shahsavar F., Tajik N., Entezami K.Z., Fallah Radjabzadeh M., Asadifar B., Alimoghaddam K., et al. KIR2DS3 is associated with protection against acute myeloid leukemia. Iran J Immunol 2010, 7:8-17.
127. Almalte Z., Samarani S., Iannello A., Debbeche O., Duval M., Infante-Rivard C., et al. Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia. Blood 2011, 118:1323-1328.
128. Besson C., Roetynck S., Williams F., Orsi L., Amiel C., Lependeven C., et al. Association of killer cell immunoglobulin-like receptor genes with Hodgkin's lymphoma in a familial study. PLoS One 2007, 2:e406.
129. Middleton D., Diler A.S., Meenagh A., Sleator C., Gourraud P.A. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens 2009, 73:553-560.
130. Cooley S., Weisdorf D.J., Guethlein L.A., Klein J.P., Wang T., Le C.T., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
131. Meyer-Monard S., Passweg J., Siegler U., Kalberer C., Koehl U., Rovo A., et al. Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation. Transfusion 2009, 49:362-371.
132. Passweg J.R., Tichelli A., Meyer-Monard S., Heim D., Stern M., Kuhne T., et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004, 18:1835-1838.
133. Rizzieri D.A., Storms R., Chen D.F., Long G., Yang Y., Nikcevich D.A., et al. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:1107-1114.
134. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. Aphase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
135. Barkholt L., Alici E., Conrad R., Sutlu T., Gilljam M., Stellan B., et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 2009, 1:753-764.
136. Iliopoulou E.G., Kountourakis P., Karamouzis M.V., Doufexis D., Ardavanis A., Baxevanis C.N., et al. Aphase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010, 59:1781-1789.